Mateon Therapeutics, Inc. Stock OTC Markets
Equities
MATN
US57667K1097
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
Sales 2022 | - | Sales 2023 | 0.07 0.1 | Capitalization | 15.27M 21.04M |
---|---|---|---|---|---|
Net income 2022 | 5M 6.89M | Net income 2023 | -7M -9.64M | EV / Sales 2022 | - |
Net Debt 2022 | 11.02M 15.18M | Net Debt 2023 | 12.4M 17.09M | EV / Sales 2023 | 395,316,686 x |
P/E ratio 2022 |
4.5
x | P/E ratio 2023 |
-1.91
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.29% |
Managers | Title | Age | Since |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 19-04-21 |
Director of Finance/CFO | 57 | 19-06-30 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 20-01-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven W. King
BRD | Director/Board Member | 59 | 20-05-10 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 20-05-10 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 19-04-21 |
1st Jan change | Capi. | |
---|---|---|
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |
- Stock Market
- Equities
- OTLC Stock
- MATN Stock